8 results about "Retinoblastoma" patented technology

GD2 specific chimeric antigen receptor effector cells for the treatment of solid tumors, possibly in combination with an enhancer of a Zeste homolog 2 (EZH2) inhibitor. The invention relates to a GD2-specific chimeric antigen receptor (GD2. CAR) effector cell for use in the treatment of solid tumors, in particular in the treatment of extracranial GD2 + tumors, such as soft tissue sarcoma and osteosarcoma, neuroblastoma, melanoma, lung cancer, bladder cancer and retinoblastoma, and brain tumors. In addition, the present invention also relates to the use of the GD2. CAR genetically modified effector cell in combination with an enhancer of a Zeste homolog 2 (EZH2) inhibitor for the treatment of solid tumors.

The invention discloses an application of a flavonoid natural product Peruvianoside I in preparation of an anti-retinoblastoma drug, belongs to the field of medicinal chemistry, and has the following structure: the compound can selectively inhibit LSD1 enzyme activity and can be used as the anti-retinoblastoma drug. Experiments find that the anti-tumor action mechanism is related to inhibition of retinoblastoma cell migration. As a selective histone lysine specific demethylase LSD1 inhibitor, the compound has the potential of developing the retinoblastoma resisting medicine.

The invention discloses an in-situ detection system for detecting EZH2 mRNA as well as a preparation method and application of the in-situ detection system. The in-situ detection system comprises a molecular probe compound and a signal amplification compound; the molecular probe compound is constructed from a dCas9-mSA fusion protein and sgRNA of a specific target EZH2 mRNA (messenger Ribonucleic Acid). The signal amplification compound is a metal organic framework nano material encapsulated with fluorescent molecules, and biotin is modified on the metal organic framework nano material; according to the molecular probe compound, Avidin in a dCas9-mSA fusion protein is specifically combined with biotin on the signal amplification compound, so that in-situ labeling and signal amplification of EZH2 mRNA (messenger Ribonucleic Acid) are realized. The in-situ detection system for detecting EZH2 mRNA provided by the invention solves the contradiction that the specificity and the sensitivity are difficult to obtain at the same time in the traditional technology, has the advantages of high sensitivity, strong specificity, good fluorescence quenching resistance, mild operation conditions and the like, can realize in-situ visual detection of tissue slice level EZH2 mRNA, and has a wide application prospect. The kit is especially suitable for auxiliary diagnosis and prognosis evaluation of retinoblastoma.

GD2-specific chimeric antigen receptor effector cells for the treatment of solid tumors, which can be combined with an Enhancer of Zeste Homolog 2 (EZH2) inhibitor. ------ The present invention relates to GD2-specific chimeric antigen receptor (GD2.CAR) effector cells for the treatment of both solid tumors, particularly extracranial GD2+ tumors (such as soft tissue sarcomas and osteosarcomas, neuroblastomas, melanomas, lung cancers, bladder cancers, and retinoblastomas) and brain tumors. Furthermore, the present invention also relates to the use of GD2.CAR gene-modified effector cells in combination with an Enhancer of Zeste Homolog 2 (EZH2) inhibitor in the treatment of solid tumors.

This invention discloses the application of BHLHE40 in the preparation of prognostic assessment kits and therapeutic drugs for retinoblastoma. Through a series of in vitro and in vivo experiments, this invention demonstrates that knocking down BHLHE40 expression significantly inhibits the proliferation of retinoblastoma cells, exhibiting a significant tumor-suppressive effect. Therefore, it is proposed that BHLHE40 inhibitors can be used in the preparation of therapeutic drugs for retinoblastoma, providing a new, effective, and safe treatment option for RB patients. Furthermore, BHLHE40 can serve as a drug target to guide subsequent drug development. In addition, this invention also utilizes clinical tumor tissue samples to demonstrate that high BHLHE40 expression is significantly positively correlated with high-risk pathological features such as optic nerve invasion, scleral invasion, and choroidal invasion, suggesting that BHLHE40 can serve as an effective biomarker for predicting high-risk pathological features, assisting physicians in treatment decisions.

The invention discloses application of a miR-3691 inhibitor in preparation of a medicine for treating retinoblastoma, and belongs to the technical field of biological medicines. The miR-3691 inhibitor is used for preparing the medicine for treating retinoblastoma, the miR-3691 inhibitor is chemically modified antisense oligonucleotide, the sequence of the miR-3691 inhibitor is shown as SEQ ID NO: 1, the miR-3691 inhibitor is realized by inhibiting proliferation and tumorigenesis of retinoblastoma cells, and the medicine takes the miR-3691 inhibitor as an active ingredient and takes the miR-3691 inhibitor as an active ingredient. The pharmaceutical composition is selected from at least one preparation form of tablets, powder, injection, capsules, suspensions, paste, gel, coating agents, medicine film agents, sustained release agents or microspheres. The miR-3691 inhibitor is proved to be capable of remarkably inhibiting the proliferation and tumorigenesis capability of retinoblastoma cells, a new clinical treatment medicine is provided for retinoblastoma, and the treatment effectiveness is improved.

The invention pertains to a binary heterojunction photosensitizer composed of graphitic carbon nitride (gCN) and black phosphorus (BP) for use in photodynamic therapy (PDT) to treat retinoblastoma. The gCN / BP binary heterojunction nanosheets enhance light absorption and charge carrier separation, activated by near-infrared (NIR) light to generate reactive oxygen species (ROS), inducing apoptosis in cancer cells. The photosensitizer accumulates selectively in tumor tissues, minimizing damage to healthy cells, and addresses BP's stability in biological environments, offering a durable, non-invasive treatment for retinoblastoma.

The application provides a preparation method and application of an anti-L1CAM antibody drug conjugate, the anti-L1CAM antibody drug conjugate comprising an anti-L1CAM single-chain antibody, a DNA / RNA hybrid chain molecule and a cytotoxin DM1; the anti-L1CAM single-chain antibody is covalently connected to one end of the DNA / RNA hybrid chain molecule; the cytotoxin DM1 is covalently connected to the other end of the DNA / RNA hybrid chain molecule; and the DNA / RNA hybrid chain molecule comprises an RNase H sensitive segment. The technical scheme of the application specifically couples the anti-L1CAM single-chain antibody and the DM1 through the DNA / RNA hybrid chain, so that the obtained antibody drug conjugate integrates targeting, intelligent release and high-efficiency killing, has the effect of inhibiting retinoblastoma proliferation, and can effectively inhibit retinoblastoma proliferation and metastasis.